John Greenman

Professor John Greenman is a tumour immunologist at the University of Hull’s Centre for Biomedicine, specializing in microfluidic technology for cancer diagnostics and personalized medicine. With over 200 peer-reviewed publications, he leads an interdisciplinary team collaborating with clinicians, chemists, and engineers. His research targets head/neck cancers and glioblastoma, exploring immune system subversion during carcinogenesis and clinical applications of lab-on-a-chip platforms.

Research Interests: Greenman’s work integrates immunobiology, microfluidics, and oncology. Key areas include:

• Developing ex vivo tumour tissue models for drug testing and biomarker discovery.
• Investigating immune evasion mechanisms in head/neck cancers and glioblastoma.
• Engineering point-of-care diagnostic devices (e.g., HCV sensors, CTC analyzers).

Publication Trends (2020s): Recent articles emphasize microfluidic innovations for clinical oncology:

• Advanced biosensors for rapid cancer/hepatitis diagnostics.
• Ex vivo perfusion systems to study radiotherapy/treatment responses.
• Extracellular vesicle biomarkers in thyroid/breast cancers.
• Epigenetic targeting in glioblastoma using perfusion-based models.

Grants & Advising: Secured £1.2M+ in active funding (e.g., Breast Cancer UK, CEPI, Brain Research UK) for projects on endocrine disruptors, SARS-CoV-2 variants, and bispecific therapeutics. Supervised 100+ postgraduate students; current team includes 11 researchers. External roles include REF panel membership (UoA3) and examinerships at De Montfort/Chester Universities.